Figure 1: Flow Diagram.

Product labels for the 17 inhibitors classified as moderate or weak per the FDA Table of Inhibitors were collected and articles were identified through a literature search. They were both then screened (e.g., abstract review) for eligibility. Records lacking exclusion criteria were assessed in more detail (e.g., full article review) for eligibility. Records were included if they were conducted in humans and reported AUC of substrate with and without the inhibitor. Each inhibitor-substrate pair that had a report of AUC was counted as one pair.

*No duplicates records present